| ●Editorial | Fukushima M | 403-4 | Full text | |
| ●Paradigms shift of drug discovery, development and lifetime management | ||||
| The key to success in translational research and critical path research Part 1: Capability of model animal in translational research Part 2: Mechanistic equality in animal disease models and human disease | Fukushima M，Kimura Y | 405-16 | Abstract | |
| The history and forecast of “Project for Translational and Clinical Research Core Centers” The ARO establishment for driving innovation mechanism, and aiming for disruptive innovation | Fukushima M | 417-28 | Abstract | |
| Academic-origin disruptive innovation and its management－ Report from the “Consolidated Strategic Management Meeting” convened by the Japan Agency for Medical Research and Development (AMED) | Fukushima M，Nakatani E， Omae K，et al． | 429-52 | Abstract | |
| Taught by a dynamism of approval history of U.S. FDA as regards the process of changing labels of new drugs | Morimoto K，Tanimura N， Haraguchi M，Ichimaru K | 453-63 | Full text | |
| ●Taiwan-Japan Academic Research Organization Workshop 2015 －Life-science innovation infrastructure and activity in Taiwan and Japan－ Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation; Academic Research Organization Council | 465-552 | Abstract | ||
| Opening remarks | Nakanishi Y | 468 | ||
| The impacting activities and infrastructure at the National Health Research Institutes, Taiwan | Yu HS | 469-74 | ||
| National Biomedical Research Parks and Taiwan Biobank | Chen CJ | 475-81 | ||
| Connecting bio-innovation with Taiwan: National Research Program for Biopharmaceuticals in Taiwan | Wang AH | 482-8 | ||
| Infrastructure and progress of translational research in Taiwan | Yang PC | 489-96 | ||
| Infrastructure of oncology translational research in Taiwan | Cheng AL | 497-503 | ||
| National infrastructure for promoting translational and clinical researches | Nagai Y | 504-9 | ||
| Approach to strengthening a translational research center in Hokkaido | Sato N | 510-4 | ||
| Advanced center for the establishment and coordination of biomedical innovation development assistance | Saito N | 515-20 | ||
| Translational Research Center for Tohoku-originated development of pharmaceutical drugs and medical devices | Shimokawa H | 521-6 | ||
| Present and future of a translational research center for network-utilized Chubu advanced medicine development | Mizuno M | 527-31 | ||
| Strengthening academia centers in drug discovery and new medical development －Achievement by Kyoto University－ | Shimizu A | 532-8 | ||
| Development of new medical seeds by Osaka University and characteristics of ARO | Myoui A | 539-44 | ||
| Establishing ARO to deliver creative next-generation medical care | Nakanishi Y | 545-51 | ||
| Closing remarks | Fukushima M | 552 | ||
| ●3rd World Centenarian Initiative International Symposium on Amyotrophic Lateral Sclerosis －Giving new hope: novel therapies toward a cure－ Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation |
553-639 | Abstract | ||
| Opening remarks | Kuzuhara S | 556 | ||
| Congratulations | Sato A Matsumoto J Yanagimoto T | 557 558 559 | ||
| Perspectives on therapeutic research for ALS | Sobue G | 560-5 | ||
| Clinical features of ALS according to the Japanese national registry for intractable and rare diseases | Sato Y | 566-71 | ||
| Neuroimaging for early diagnosis of ALS | Sasaki M | 572-5 | ||
| Discussion | 576-7 | |||
| The role of ALS patient associations in funding and facilitating clinical research | Dickie B | 578-87 | ||
| Development of specific therapy for sporadic ALS | Kwak S | 588-93 | ||
| Preliminary investigation of safety and efficacy of Fasudil® in subjects with ALS | Fan D | 594-8 | ||
| Discussion | 599-601 | |||
| Immune-inflammatory modulation as a therapeutic strategy of stem cell therapy in ALS | Kim SH | 602-10 | ||
| Regenerative therapies for ALS using hepatocyte growth factor | Suzuki N | 611-6 | ||
| Overview of US clinical trials for ALS－What can we learn from them? | Banno H | 617-23 | ||
| Brain-machine interface (BMI) for ALS patients | Yoshimine T，Hirata M | 624-9 | ||
| Cybernic neurorehabilitation using Hybrid Assistive Limb (HAL) for the patients with neuromuscular disease | Nakajima T | 630-6 | ||
| Closing remarks | Fukushima M | 637-9 | ||
| ●Instructions for authors［Japanese］＆［English］ | 641-9 | Full text | ||
| ●Editor’s note | Takeuchi M | 651 | Full text | |